MA-TA-ASSOCIATES
8.2.2021 17:02:06 CET | Business Wire | Press release
TA Associates, a leading global growth private equity firm, today announced that it has entered exclusive negotiations to make a majority growth investment in DL Software, a leading France-based group of enterprise resource planning (ERP) software providers. Current DL Software majority shareholder 21 Invest France, as well as company founders and management, would each retain a stake in the business following TA’s investment. The envisaged transaction, which is currently under review by representatives of the company’s employees, is expected to close in the second quarter of 2021, subject to customary approvals. Financial terms were not disclosed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210208005585/en/
“DL Software has become a leading B2B software player in France through a longstanding strategy of acquiring and growing highly-verticalized ERP vendors,” said Maxime Cancre, a Principal at TA Associates who would join the DL Software Board of Directors. “We are pleased to announce this prospective investment and look forward to partnering with DL Software management and our fellow investors in actively seeking new growth opportunities for the company.”
“It is a pleasure to have the opportunity to welcome TA Associates as an investor in DL Software,” said Jacques Ollivier, President of DL Software. “DL has developed significantly in recent years, both organically and inorganically, and we are excited to combine our know-how with TA’s software investing experience with an aim to deliver sustained strong performance for years to come. With the support of our investors, DL will continue to seek additional acquisition opportunities in France and may consider other markets in Europe.”
“We have been very impressed with the development of DL Software under the ownership of 21 Invest France and its co-investors, Amundi Private Equity Funds and Swen Capital Partners, and the leadership of Jacques Ollivier,” said Patrick Sader, a Managing Director at TA Associates who would also join the DL Software Board of Directors. “DL Software enjoys a high-quality revenue model and the French ERP market is large, so we see meaningful expansion opportunities for the company. We are very excited to embark on this journey.”
“I join the DL Software team in welcoming TA as a future investor,” said Stephane Perriquet, Managing Partner at 21 Invest France. “We have enjoyed collaborating with DL Software, helping to grow the company’s market share over the past several years, and look forward to this next phase in the continuing evolution of the company.”
De Pardieu Brocas Maffei served as legal counsel, DC Advisory as M&A advisor and Eight Advisory as financial advisors to DL Software and its shareholders. Latham & Watkins served as legal counsel, Bryan Garnier as M&A advisor and KPMG as financial and tax advisor to TA Associates. Jausserand Audouard and Oloryn advised management.
About DL Software
Founded in 2003, DL Software is a specialist in business ERP. The group has 13 independent and specialized companies whose solutions address more than 30 vertical sectors, including health, insurance, retail, trading, real estate and tourism. Since its founding, DL Software has realized an average annual growth rate of more than 10%. For more information, please visit www.dlsoftware.fr
.
About TA Associates
TA Associates is a leading global growth private equity firm. Focused on targeted sectors within five industries – technology, healthcare, financial services, consumer and business services – TA invests in profitable, growing companies with opportunities for sustained growth, and has invested in more than 500 companies around the world. Investing as either a majority or minority investor, TA employs a long-term approach, utilizing its strategic resources to help management teams build lasting value in high quality growth companies. TA has raised $33.5 billion in capital since its founding in 1968 and is committing to new investments at the pace of over $3 billion per year. The firm’s more than 100 investment professionals are based in Boston, Menlo Park, London, Mumbai and Hong Kong. DL Software will be TA’s eleventh investment in France since 2009. More information about TA Associates can be found at www.ta.com
.
About 21 Invest
An active shareholder alongside management teams, 21 Invest supports companies based in France, Italy and Poland and accompanies them into new stages of development. Over the last 29 years, 21 Invest has realized more than 105 investments. In France, 21 Invest invests in growing and resilient SMEs in the healthcare, business services, and technology sectors. More information about 21 Invest can be found at www.21invest.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210208005585/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Angel Aligner Unveils Six Innovations for 202711.11.2026 17:23:00 CET | Press release
Angel Elevates the Orthodontic Specialty by Focusing on Complex-Case Solutions Angelalign Technology Inc. (6699.HK) (“Angel”), a global clear aligner leader, has unveiled six new clinical innovations, including SuperElastic (MC-SE)* aligner material, a Deepbite Solution for significantly expanded indications, and the Adapt-MATMsystem for next generation growth guidance for young patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110338654/en/ Unveiling Angel's 2027 Innovations. Orthodontists and opinion leaders have long remarked about Angel’s clinical excellence. Orthodontics educator and thought leader Dr. David Sarver said: “In over 4 decades, I’ve never had a parent say I’d be happy if you ensure that my child’s treatment results are average.” Angel is committed to elevating the orthodontic specialty well above the average, especially as more competition and harder referral cases demand outstanding results. Bind
Abu Dhabi Future Health Summit Concludes with Research Partnerships and New Programmes to Advance Prevention and Health Innovation11.11.2026 15:58:00 CET | Press release
Partnerships span drug discovery, clinical research, preventive and reproductive health Launch of an AI Clinician Framework and a Trusted Research Environment for health and genomic data Four whitepapers address genomics, therapeutics, fertility and wearable technologies New programmes support health innovators and entrepreneurs More than 17,300 visitors from 85 countries, with 130 speakers across 45 sessions Held under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council, Abu Dhabi Future Health Summit 2026 concluded with agreements and initiatives spanning drug discovery, clinical research, preventive and reproductive health, alongside research and entrepreneurship programmes that will sustain collaboration beyond the Summit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111545964/en/ The Summit is the annual flagship gath
De' Longhi Group: Record Results for the Quarter, With Revenue Growing by 7.7% and Net Profit Pertaining to the Group Progressing Significantly by 19%11.11.2026 15:58:00 CET | Press release
The Board of Directors of De' Longhi S.p.A. approved the consolidated results1 for the nine months of 2026. In the nine months the Group achieved: revenues for € 2,621.3 million, up by 6.5% with respect to 2025 (+7.7% at constant currency); an adjusted2 Ebitda of € 455.2 million, equal to 17.4% on revenues (vs. 15.8% with respect to last year); a net income pertaining to the Group equal to € 225.8 million (+20.4% with respect to last year); a positive net financial position equal to € 606.0 million. CEO Fabio de' Longhi commented: “The Group delivered its thirteenth consecutive quarter of organic revenue growth, underscoring our proven ability to capitalize on industry opportunities and respond promptly to market evolution, while ensuring consistent performance across both divisions. The professional business recorded a strong acceleration, spanning all geographies and brands, with revenues growth exceeding 35% for both the quarter and the nine-month period, this against an already par
Starr Chile Assigned A Rating from AM Best11.11.2026 14:30:00 CET | Press release
Starr, a global insurance and investment organization, today announced that the global credit rating agency AM Best has assigned Starr International Seguros Generales S.A. (Starr Chile) a Financial Strength Rating of A (Excellent) and a Long-Term Issuer Credit Rating of a+ (Excellent). The outlook for both credit ratings is positive. The rating reflects Starr’s strong balance sheet and Starr Chile’s successful implementation of Starr’s business model. AM Best also cited Starr’s operating performance, a favorable business profile and enterprise risk management as key factors supporting the positive rating. “This strong rating is another important endorsement of Starr’s business model as we continue to build our presence in Latin America,” said Jeff Greenberg, chairman and co-CEO of Starr. “It reflects the financial strength, underwriting discipline and experienced teams that underpin our business around the world, reinforcing the confidence brokers and clients can place in Starr.” Starr
Epinal, Inc. Emerges from Stealth with First-of-Its-Kind Breakthrough Semiconductor Electrochemical Biosensor (SEB) for Detection of Narcotics and Disease Biomarkers in Human Breath in Minutes11.11.2026 14:22:00 CET | Press release
Southern California-Based Company has developed a disruptive biosensor for integration into next-generation screening and diagnostic devices Epinal, Inc., after over six years of under-the-radar development, has officially emerged from stealth mode, introducing a breakthrough Semiconductor Electrochemical Biosensor (SEB) designed to detect narcotics and disease biomarkers directly from human breath in minutes. By combining advanced semiconductors, electrochemical sensing, tailored protein engineering, and artificial intelligence, Epinal has addressed the historical sensitivity, selectivity, scaling, stability, and signal-to-noise limitations that have long bottlenecked biosensors. Epinal’s Semiconductor Electrochemical Biosensor (SEB) will be integrated into the next generation of low cost, disposable, single-use breathalyzer cartridges where the integrity of test results is of utmost importance. In the case of narcotic detection, a rapid, non-invasive, and objective result changes an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom